Adam’s Take
Insights and opinions from senior biotech writer Adam Feuerstein
Most Read
Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies
Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent
An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more
An FDA rejection derails Omeros, exposing the empty promises of its CEO
In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s
The failure of a cancer drug study leaves Cel-Sci on the brink of collapse
Fibrogen’s data manipulation scandal came with questions. There need to be answers
All Coverage
advertisement
